Recently, high NRF2 expression in NSCLC patients were found to be correlated with poorer OS and PFS following chemotherapy or EGFR TKIs treatment, suggesting NRF2 as a potential marker of tumor aggressiveness and a valuable tool for prognosis and optimizing treatment strategies [205]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.